Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
June 01 2022 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading
clinical-stage CRISPR genome-editing biopharmaceutical company,
today announced that the company will host a webcast conference
call to share additional initial clinical data from its ANTLER
Phase 1 clinical trial of CB-010 in patients with relapsed or
refractory B cell non-Hodgkin lymphoma (r/r B-NHL) on Friday, June
10, 2022, at 8:00 am ET. The discussion will include longer
duration data on the six patients treated at dose level 1 based on
a new data cutoff date.
Webcast presenters will include:
- Rachel Haurwitz, Ph.D., president and chief executive officer,
Caribou
- Syed Rizvi, M.D., chief medical officer, Caribou
- Steven Kanner, Ph.D., chief scientific officer, Caribou
- Loretta J. Nastoupil, M.D., section chief of new drug
development; associate professor, Department of Lymphoma/Myeloma,
The University of Texas MD Anderson Cancer Center
- James H. Essell, M.D., OHC hematologist, medical oncologist,
blood and marrow transplant specialist, and Chair, Cellular
Therapy, US Oncology Network
The live webcast and conference call at 8:00 am ET, with an
accompanying presentation, will be accessible under Events in the
Investors section of the company’s website. To participate in the
conference call, dial 1-844-862-9351 (domestic) or 1-929-517-0932
(international) and reference conference ID #4657536. The archived
audio webcast will be available on Caribou’s website following the
call and will be available for 30 days.
Details of the poster presentation at EHA are as
follows:Title: First-in-human trial of
CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy
with a PD-1 knock out, in patients with relapsed or refractory B
cell non-Hodgkin lymphoma (ANTLER study) Abstract:
3103Presenter: Loretta J. Nastoupil,
M.D.Date and Time: Friday, June 10, 2022, 16:30 –
17:45 CEST (10:30 – 11:45 am ET)Session Title:
Gene therapy, cellular immunotherapy and vaccination -
ClinicalLocation: Messe Wien Exhibition &
Congress Center, Vienna, Austria
Presentations and posters will be available for registered
attendees of EHA for on-demand viewing on the EHA website on June
10, 2022 at 9:00 am CEST (3:00 am ET). Caribou plans to issue a
data press release at 9:00 am CEST (3:00 am ET) on Friday June 10,
2022. The poster will be available on the Presentations page of the
Investors section of Caribou’s website.
About CB-010CB-010 is the lead product
candidate from Caribou’s allogeneic CAR-T cell therapy platform and
is being evaluated in patients with relapsed or refractory B cell
non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1
trial. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy
engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to
insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to
boost the persistence of antitumor activity. CB-010 is the first
allogeneic CAR-T cell therapy in the clinic with a PD-1 knock out.
Additional information on the ANTLER trial can be found at
https://clinicaltrials.gov using identifier NCT04637763.
About Caribou’s Novel Next-Generation CRISPR
Platform CRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited
therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans, and objectives,
and expectations regarding its clinical and preclinical development
programs, including its expectations relating to the timing of the
release of initial and additional patient data from its ANTLER
phase 1 clinical trial for CB-010. Management believes that these
forward-looking statements are reasonable as and when made.
However, such forward-looking statements are subject to risks and
uncertainties, and actual results may differ materially from any
future results expressed or implied by the forward-looking
statements. Risks and uncertainties include, without limitation,
risks inherent in development of cell therapy products;
uncertainties related to the initiation, cost, timing, progress,
and results of Caribou’s current and future research and
development programs, preclinical studies, and clinical trials; and
the risk that initial or interim clinical trial data will not
ultimately be predictive of the safety and efficacy of Caribou’s
product candidates or that clinical outcomes may differ as more
patient data becomes available; as well as other risk factors
described from time to time in Caribou’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the year ended December 31, 2021, and subsequent
filings. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. Except
as required by law, Caribou undertakes no obligation to update
publicly any forward-looking statements for any reason.
Caribou Biosciences,
Inc. |
Contacts: |
Amy Figueroa, CFA |
Investor Relations and Corporate
Communications |
afigueroa@cariboubio.com |
|
Investors and
Media: |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Wheelhouse LSA |
lwolffe@wheelhouselsa.com |
swheeler@wheelhouselsa.com |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024